Effect of naloxone therapy on depersonalization: a pilot study

  title={Effect of naloxone therapy on depersonalization: a pilot study},
  author={Yu.L. Nuller and M G Morozova and O. N. Kushnir and Nikita Hamper},
  journal={Journal of Psychopharmacology},
  pages={93 - 95}
To test the hypothesis of the role for the opioid system in the pathogenesis of depersonalization, the effect of naloxone (an opioid receptor blocker) on the symptoms and corticosteroids secretion was studied in patients with depersonalization syndrome. Fourteen depersonalization patients were treated with naloxone: 11 patients received single doses (1.6 or 4 mg i.v.) and three others received multiple infusions, with the maximal dosage being 10 mg, and the effect of naloxone on symptom… 

Tables from this paper

An Open Trial of Naltrexone in the Treatment of Depersonalization Disorder

There was an average 30% reduction of symptoms with treatment, as measured by 3 validated dissociation scales, and these findings are potentially promising in a highly treatment-refractory disorder for which no treatment guidelines exist and warrant a randomized controlled trial.

Evaluation of naltrexone for dissociative symptoms in borderline personality disorder

The data provide the first estimate of the pure pharmacological antidissociative efficacy of naltrexone from a rigorously designed trial.

Methylphenidate in depersonalization disorder: a case report.

A case that responded spectacularly to methylphenidate is presented, with virtually no evidence, and among the many psychoactive drugs studied, none of them has been shown to be the treatment of choice.

Depersonalization disorder: pharmacological approaches

  • M. Sierra
  • Psychology, Biology
    Expert review of neurotherapeutics
  • 2008
A number of studies suggest that opioid receptor antagonists such as naltrexone and naloxone are useful in at least a subgroup of patients, and those neurotransmitter systems of relevance to depersonalization are known to play important inhibitory roles in the regulation of the stress response.

Lamotrigine in the immediate treatment of outpatients with depersonalization disorder without psychiatric comorbidity: randomized, double-blind, placebo-controlled study.

This is believed to be the first double-blind placebo-controlled randomization study to test the efficacy of lamotrigine in the management of outpatients with DPDs and the results need to be replicated in a larger study group.

The Potential Role of Naltrexone in Borderline Personality Disorder

Naltrexone (NTX), a nonspecific competitive opiate antagonist, has been noted to be helpful in controlling self-injurious behavior (SIB) and dissociative symptoms in patients with BPD.

The efficacy of lamotrigine in a resistant case of depersonalization disorder.

A resistant case that responded to lamotrigine is presented, among the many psychoactive drugs studied, none of them has been shown to be the treatment of choice.



Depersonalisation ‐ symptoms, meaning, therapy

  • Y. Nuller
  • Psychology
    Acta psychiatrica Scandinavica
  • 1982
The data indicate that depersonalisation results from anxiety; it follows an anxiety attack and is successfully treated with anxiolytic drugs, and in the case of endogenous depression, depersonalisaticm leads to lingering depressive phase, increasing the patients resistance to antidepressive therapy.


Since the discovery of endorphins, a number of hypotheses relating these substances to mental illness have been formulated and the administration of opioid antagonists has been used as a tool to test some of these hypotheses.

Unresponsiveness of catatonic symptoms to naloxone.

Testing of catatonic patients with naloxone may help further elucidate nAloxone's reported anti-psychotic properties.

[Study of pain sensitivity based on the indicators of electro- odontometry in patients with depersonalization and depressive disorders].

: Electroodontometry was used to examine the pain threshold and sensation threshold in patients with depersonalization, endogenous depression and in mentally healthy test subjects. The strongest

Behavioral effects of opioid receptor antagonists in psychopathologic states.

Oxford textbook of psychiatry

Signs and symptoms of mental disorder interviewing, clinical examination and record keeping classification in psychiatry aetiology personality disorder neurosis affective disorders schizophrenia and

Opioid peptide and alpha-adrenoceptor pathways in the regulation of the pituitary-adrenal axis in man.

A study into the interaction of methoxamine, an alpha 1-adrenoceptor agonist and naloxone, an opioid antagonist, together with human corticotrophin-releasing hormone (CRH), in a group of healthy volunteers to establish the mode of action of these drugs.

Indices of pain threshold as a method of objective assessment of depersonalization therapy efficacy

  • Bekhterev Rev Psychiatry Med Psychol
  • 1996